[Closed for Investment] Winsantor is here to make sure that no one suffers from peripheral neuropathy (PN). PN affects 1 in 15 people in the US, and it’s when the nerves die due to disease, injuries, cancer, or genetic diseases. There is currently no treatment -- just drugs that help reduce the pain. Winsantor, however, is currently in trials that show they be on track to reverse the disease, both biologically and functionally. So far, over $30M of non-dilutive funding has driven R&D; they are currently entering Phase 2 of early efficacy studies; and they aim to have their drug approved by 2021 to start helping -- and changing -- the lives of those who are affected.